A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults

Trial Profile

A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2018

At a glance

  • Drugs Avibactam/ceftazidime (Primary) ; Metronidazole (Primary) ; Meropenem
  • Indications Bacterial infections; Intra-abdominal infections
  • Focus Registrational; Therapeutic Use
  • Acronyms RECLAIM3
  • Sponsors AstraZeneca
  • Most Recent Events

    • 14 Jun 2018 Results (n=2585) of pooled data (RECLAIM 1, RECLAIM 2, REPROVE, REPRISE, RECAPTURE 1 and RECAPTURE 2) published in the Journal of Antimicrobial Chemotherapy
    • 28 Jun 2016 According to AstraZeneca media release, the European Commission has granted marketing authorisation for Zavicefta (ceftazidime-avibactam, previously known as CAZ AVI), a new combination antibiotic for the treatment of patients with serious Gram-negative bacterial infections requiring hospitalisation.
    • 23 Jun 2016 Results published in an Allergen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top